Ampeptec

Ampeptec is a preclinical-stage biotechnology company specializing in the development of innovative, long-acting peptide therapeutics for metabolic diseases, specifically obesity and diabetes. The company's lead candidate, APT3711, is a fully synthetic GLP-1 receptor agonist engineered with unnatural amino acids to enhance stability and half-life, designed as a potential once-monthly injectable or once-weekly oral treatment. Additionally, Ampeptec is developing APT3598, a once-weekly insulin analog synthesized using a proprietary chemical synthesis method that incorporates unnatural amino acids to improve stability and double its half-life. Led by industry veterans with extensive experience in peptide drug development and manufacturing, Ampeptec is actively seeking strategic partnerships to advance its pipeline into clinical development.